Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eos Energy Enterprises Inc (EOSE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Eos Energy Enterprises IncTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Eos Energy Enterprises Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Eos Energy Enterprises Inc trades at $4.02 (market cap $1.55B), while State Street SPDR S&P Biotech ETF trades at $151.88. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals.

EOSEXBI
Market Cap
$1.55B
Sector
EnergyBroad Market / Factor
52-Week High
$19.19$164.28
52-Week Low
$4.29$85.16
Enterprise Value
$1.79B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eos Energy Enterprises Inc

Eos Energy Enterprises (EOSE) trades at $3.99, down 6.99% on the day, reflecting a challenging fundamental picture with significant losses. The company reported a net loss of $969.65M on $114.20M revenue for 2025, though recent Q1 2026 results showed a surprise EPS beat. Technical indicators are predominantly bearish, with moving averages signaling strong selling pressure, while the stock is consolidating near a key $4 support level. Recent news highlights accelerating commercial execution, including a major project selection for the Golden Dome initiative and preliminary Q2 2026 results pointing to record quarterly revenue and backlog.

The outlook presents a high-risk, high-reward scenario. Significant revenue acceleration and project backlog growth offer potential upside, supported by a consensus analyst price target of $9.00 (125% upside). However, deep negative margins, substantial cash burn, and a highly leveraged balance sheet with 91.87% debt-to-asset ratio pose severe financial risks. Investment success hinges on the company's ability to achieve manufacturing scale and path to profitability in the competitive energy storage market.

State Street SPDR S&P Biotech ETF

XBI (SPDR S&P Biotech ETF) trades at $152.07, down 2.23% today, but maintains a bullish technical outlook with strong momentum indicators. The ETF has gained significant attention with a 17% monthly surge, driven by biotech sector strength and increased M&A activity. Analyst coverage shows a cautious stance with 100% hold rating, reflecting balanced risk-reward assessment amid sector volatility.

The biotech sector shows strong momentum with AI drug discovery advances and record M&A activity ($106 billion in 2026). While XBI offers high-beta exposure to small/mid-cap biotech growth, investors face elevated volatility and regulatory uncertainties. The equal-weight portfolio structure provides diversified exposure to sector innovation but requires tolerance for price swings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eos Energy Enterprises Inc

Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.

Read more on EOSE

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI